trial

BXCL501 for Agitation in Schizophrenia

NCTId NCT03708315
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 11 (actual)
Sponsored by Yale University
Primary completion 2023-05-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
11 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2020-03-09
Primary completion
2023-05-26
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Dexmedetomidine Hydrochloride

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Mohini Ranganathan, MBBSPrincipal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
11
Phase
PHASE1
Primary Completion Date
2023-05-26
Status
COMPLETED
relationships
The graph out of here
drug
Dexmedetomidine Hydrochloride
drug
lead_sponsor
Yale University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Mohini Ranganathan, MBBS
person